Matt Hewitt
Stock Analyst at Craig-Hallum
(2.57)
# 2,236
Out of 4,944 analysts
40
Total ratings
51.35%
Success rate
1.86%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $14.44 | +149.31% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $6.72 | +78.57% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $2.63 | +128.57% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $24.87 | +28.67% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $31.10 | +105.79% | 6 | Oct 31, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $1.94 | +416.80% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $19.58 | +53.22% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $1.40 | +401.79% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $124.55 | +60.58% | 3 | Aug 3, 2023 | |
| OABI OmniAb | Initiates: Buy | $10 | $2.05 | +387.80% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $7.39 | +305.95% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.16 | +34,532.03% | 1 | Jan 4, 2022 |
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $14.44
Upside: +149.31%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $6.72
Upside: +78.57%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.63
Upside: +128.57%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $24.87
Upside: +28.67%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $31.10
Upside: +105.79%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $1.94
Upside: +416.80%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $19.58
Upside: +53.22%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $1.40
Upside: +401.79%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $124.55
Upside: +60.58%
OmniAb
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $2.05
Upside: +387.80%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $7.39
Upside: +305.95%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $1.16
Upside: +34,532.03%